These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 36671478)

  • 21. A novel 4-aminoquinazoline derivative, DHW-208, suppresses the growth of human breast cancer cells by targeting the PI3K/AKT/mTOR pathway.
    Wang S; Zhang Y; Ren T; Wu Q; Lu H; Qin X; Liu Y; Ding H; Zhao Q
    Cell Death Dis; 2020 Jun; 11(6):491. PubMed ID: 32606352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway.
    Du L; Li X; Zhen L; Chen W; Mu L; Zhang Y; Song A
    Mol Med Rep; 2018 May; 17(5):7163-7169. PubMed ID: 29568883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent clinical advances in PI3K inhibitors on colorectal cancer.
    Zhu M; Jin Q; Xin Y
    Pharmazie; 2021 Dec; 76(12):568-573. PubMed ID: 34986950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extract from Astragalus membranaceus inhibit breast cancer cells proliferation via PI3K/AKT/mTOR signaling pathway.
    Zhou R; Chen H; Chen J; Chen X; Wen Y; Xu L
    BMC Complement Altern Med; 2018 Mar; 18(1):83. PubMed ID: 29523109
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benzo[b]furan derivatives induces apoptosis by targeting the PI3K/Akt/mTOR signaling pathway in human breast cancer cells.
    Kamal A; Lakshma Nayak V; Nagesh N; Vishnuvardhan MV; Subba Reddy NV
    Bioorg Chem; 2016 Jun; 66():124-31. PubMed ID: 27149364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts.
    McKenna M; McGarrigle S; Pidgeon GP
    Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):185-197. PubMed ID: 30318472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lupiwighteone induces caspase-dependent and -independent apoptosis on human breast cancer cells via inhibiting PI3K/Akt/mTOR pathway.
    Won YS; Seo KI
    Food Chem Toxicol; 2020 Jan; 135():110863. PubMed ID: 31604113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.
    Guerrero-Zotano A; Mayer IA; Arteaga CL
    Cancer Metastasis Rev; 2016 Dec; 35(4):515-524. PubMed ID: 27896521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.
    Hernandez-Aya LF; Gonzalez-Angulo AM
    Oncologist; 2011; 16(4):404-14. PubMed ID: 21406469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural products attenuate PI3K/Akt/mTOR signaling pathway: A promising strategy in regulating neurodegeneration.
    Fakhri S; Iranpanah A; Gravandi MM; Moradi SZ; Ranjbari M; Majnooni MB; Echeverría J; Qi Y; Wang M; Liao P; Farzaei MH; Xiao J
    Phytomedicine; 2021 Oct; 91():153664. PubMed ID: 34391082
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PI3K-AKt-mTOR Pathway and New Tools to Prevent Acquired Hormone Resistance in Breast Cancer.
    Nicolini A; Ferrari P; Kotlarova L; Rossi G; Biava PM
    Curr Pharm Biotechnol; 2015; 16(9):804-15. PubMed ID: 26201609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
    Saini KS; Loi S; de Azambuja E; Metzger-Filho O; Saini ML; Ignatiadis M; Dancey JE; Piccart-Gebhart MJ
    Cancer Treat Rev; 2013 Dec; 39(8):935-46. PubMed ID: 23643661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 6-Methoxydihydrosanguinarine induces apoptosis and autophagy in breast cancer MCF-7 cells by accumulating ROS to suppress the PI3K/AKT/mTOR signaling pathway.
    Zhang L; Zhang X; Che D; Zeng L; Zhang Y; Nan K; Zhang X; Zhang H; Guo Z
    Phytother Res; 2023 Jan; 37(1):124-139. PubMed ID: 36116140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.
    Pierobon M; Ramos C; Wong S; Hodge KA; Aldrich J; Byron S; Anthony SP; Robert NJ; Northfelt DW; Jahanzeb M; Vocila L; Wulfkuhle J; Gambara G; Gallagher RI; Dunetz B; Hoke N; Dong T; Craig DW; Cristofanilli M; Leyland-Jones B; Liotta LA; O'Shaughnessy JA; Carpten JD; Petricoin EF
    Clin Cancer Res; 2017 Aug; 23(16):4919-4928. PubMed ID: 28446508
    [No Abstract]   [Full Text] [Related]  

  • 38. Natural Products as PI3K/ Akt Inhibitors: Implications in Preventing Hepatocellular Carcinoma.
    Narayanankutty A
    Curr Mol Pharmacol; 2021; 14(5):760-769. PubMed ID: 33494690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting PI3K/AKT/mTOR-mediated autophagy for tumor therapy.
    Xu Z; Han X; Ou D; Liu T; Li Z; Jiang G; Liu J; Zhang J
    Appl Microbiol Biotechnol; 2020 Jan; 104(2):575-587. PubMed ID: 31832711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer.
    Lauring J; Park BH; Wolff AC
    J Natl Compr Canc Netw; 2013 Jun; 11(6):670-8. PubMed ID: 23744866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.